[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"type2-diabetes\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:type2-diabetes":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,10,0,[8,70,99,122,156,178,208,232,259,284],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":17,"sex":18,"minAge":19,"maxAge":20,"enrollmentInfo":21,"targetDuration":4,"studyType":24,"phases":4,"briefSummary":25,"conditions":26,"keywords":43,"overallStatus":57,"whyStopped":4,"lastUpdateSubmitDate":58,"lastUpdatePostDateStruct":59,"startDateStruct":62,"completionDateStruct":64,"leadSponsor":66,"locationsCount":69},"100346729","psychosocial-environmental-and-chronic-disease-trends-in-puerto-rico-100346729",false,"NCT03794531","Psychosocial, Environmental, and Chronic Disease Trends in Puerto Rico","Puerto Rico Observational Study of Psychosocial, Environmental, and Chronic Disease Trends","PROSPECT","Inclusion Criteria:\n\n1. Age 30-75 years old at the time of enrollment\n2. Non-institutionalized\n3. Living in PR at the time of the first interview and the year before and not planning to move from the island within 3 years\n4. Able to answer questions without assistance\n5. Living in a stable dwelling\n\nExclusion Criteria:",true,"ALL","30 Years","75 Years",{"count":22,"type":23},2500,"ESTIMATED","OBSERVATIONAL","The overall goal is to identify trends and longitudinal associations in psychosocial, food-related, and cardiometabolic risk factors that can guide public health priorities and future research needs aimed at reducing cardiovascular-related disparities in Puerto Rico. To this end, investigators will establish 'PROSPECT: Puerto Rico Observational Study of Psychosocial, Environmental, and Chronic disease Trends', an island-wide, longitudinal population cohort of 2,500 adults (30-75 years) in PR recruited with a community-wide sampling strategy, and assessed in a network of several partner clinics across the island. The study will collect comprehensive data on multiple psychosocial, dietary, and food-related factors, CVD biological markers, and medical record data, with follow-up at 2-years, and will assess variations by urban-rural area and by timing before-after Maria.",[27,28,29,30,31,32,33,34,35,36,37,38,39,40,41,42],"Heart Diseases","Type2 Diabetes","Hypertension","Obesity","Dyslipidemias","Metabolic Syndrome","Cardiovascular Diseases","Chronic Disease","Inflammation","Psychological Stress","Physiological Stress","Depressive Symptoms","Coping Behavior","Diet Habit","Lifestyle","Food Insecurity",[44,45,46,47,48,49,50,51,52,53,54,55,56],"Hispanics\u002FLatinos","Minority health","Puerto Rico","Cardiovascular disease","Cardiometabolic health","Chronic disease risk factors","Disaster research","Caribbean and Latin America","Population health","Prospective study","Allostatic load","Food insecurity","Longitudinal study","RECRUITING","2026-04-30",{"date":60,"type":61},"2026-05-05","ACTUAL",{"date":63,"type":61},"2019-03-01",{"date":65,"type":23},"2029-04-30",{"name":67,"class":68},"Harvard School of Public Health (HSPH)","OTHER",1,{"id":71,"slug":72,"hasResults":11,"nctId":73,"briefTitle":74,"officialTitle":75,"acronym":4,"eligibilityCriteria":76,"healthyVolunteers":11,"sex":18,"minAge":77,"maxAge":78,"enrollmentInfo":79,"targetDuration":4,"studyType":81,"phases":82,"briefSummary":84,"conditions":85,"keywords":87,"overallStatus":57,"whyStopped":4,"lastUpdateSubmitDate":90,"lastUpdatePostDateStruct":91,"startDateStruct":93,"completionDateStruct":95,"leadSponsor":97,"locationsCount":69},"100443699","early-phase-1-sglt2-inhibitors-ketones-and-cardiovascular-benefit-research-plan-100443699","NCT05057806","SGLT2 Inhibitors, Ketones, and Cardiovascular Benefit Research Plan","Sodium-glucose Cotransporter-2 (SGLT2) Inhibitors, Ketones, and Cardiovascular Benefit Research Plan","Inclusion Criteria:\n\n* Type 2 Diabetes Mellitus\n* Class II-III New York Heart Association (NYHA) heart failure and reduced ejection fraction (EF) \\\u003C50%\n* Age 18-80 years\n* BMI 23-38 kg\u002Fm2\n* Glycated hemoglobin (HbA1c) 5.5-10%\n* Blood Pressure (BP) ≤ 145\u002F85 mmHg\n* Estimated glomerular filtration rate (eGFR) ≥30 ml\u002Fmin•1.73 m2\n* Stable dose of guideline-directed medications for heart failure and Diabetes\n* Stable body weight (±4 pounds) over the last 3 months\n* Does not suffer from severe claustrophobia\n* No contraindication for MRI (metal plates, screws, shrapnel, pins, or cardiac pacemaker)\n\nExclusion Criteria:\n\n* Subjects treated with an SGLT2 inhibitor, a glucagon-like peptide-1 receptor agonist (GLP-1 RA) or pioglitazone\n* Pregnancy, lactation or plans to become pregnant\n* Allergy\u002Fsensitivity to study drugs or their ingredients\n* Cancer\n* Current drug or alcohol use or dependence\n* Inability or unwillingness of individual or legal guardian\u002Frepresentative to give written informed consent","18 Years","80 Years",{"count":80,"type":23},30,"INTERVENTIONAL",[83],"EARLY_PHASE1","The study team will examine the effects of SGLT2i (and SGLT2i-induced increases in plasma ketone concentrations) on skeletal muscle and cardiac ketone uptake, skeletal muscle bioenergetics, cardiopulmonary exercise capacity, and patient-reported functional outcomes.",[28,86],"Heart Failure With Preserved Ejection Fraction",[88,89],"Ketones","Cardiovascular benefit","2026-03-30",{"date":92,"type":61},"2026-04-06",{"date":94,"type":61},"2021-01-13",{"date":96,"type":23},"2027-03-31",{"name":98,"class":68},"The University of Texas Health Science Center at San Antonio",{"id":100,"slug":101,"hasResults":11,"nctId":102,"briefTitle":103,"officialTitle":103,"acronym":4,"eligibilityCriteria":104,"healthyVolunteers":11,"sex":18,"minAge":77,"maxAge":4,"enrollmentInfo":105,"targetDuration":4,"studyType":24,"phases":4,"briefSummary":107,"conditions":108,"keywords":110,"overallStatus":57,"whyStopped":4,"lastUpdateSubmitDate":112,"lastUpdatePostDateStruct":113,"startDateStruct":115,"completionDateStruct":117,"leadSponsor":119,"locationsCount":121},"100322697","a-causative-role-for-amylin-in-diabetic-peripheral-neuropathy-100322697","NCT03481283","A Causative Role for Amylin in Diabetic Peripheral Neuropathy","Inclusion Criteria:\n\n* Subject has been diagnosed with Type-2 Diabetes.\n* Subject shows mild-to-severe peripheral neuropathy, as determined by Nerve Conduction Velocity (NCV) tests.\n\nExclusion Criteria:\n\n* Subject has not been diagnosed with Type-2 Diabetes.\n* Subject shows average, or above average performance on Nerve Conduction Velocity (NCV) tests.",{"count":106,"type":23},40,"Three pieces of information lead to the basis for this study:\n\n1. Individuals with Type-2 diabetes commonly develop peripheral neuropathy.\n2. Increased production of the hormone amylin occurs in individuals who have Type-2 diabetes.\n3. Aggregations of amylin was found in the peripheral vasculature of rats that overexpressed human amylin.\n\nThe purpose of this study is to determine whether a correlation exists between the amount of amylin present in the upper extremities of human subjects with Type-2 diabetes and the extent to which symptoms of peripheral neuropathy are expressed in those subjects. The investigators will be testing this by initially collecting blood and skin biopsy samples from subjects, followed by measuring patient sensation and pain responses to heat, cold, and pressure in the upper extremities.",[28,109],"Peripheral Neuropathy",[111],"Amylin","2026-01-28",{"date":114,"type":61},"2026-01-30",{"date":116,"type":61},"2018-02-05",{"date":118,"type":23},"2029-01",{"name":120,"class":68},"Zabeen Mahuwala, MD",2,{"id":123,"slug":124,"hasResults":11,"nctId":125,"briefTitle":126,"officialTitle":127,"acronym":128,"eligibilityCriteria":129,"healthyVolunteers":17,"sex":18,"minAge":130,"maxAge":131,"enrollmentInfo":132,"targetDuration":4,"studyType":24,"phases":4,"briefSummary":134,"conditions":135,"keywords":145,"overallStatus":57,"whyStopped":4,"lastUpdateSubmitDate":147,"lastUpdatePostDateStruct":148,"startDateStruct":150,"completionDateStruct":152,"leadSponsor":154,"locationsCount":121},"100460586","brain-health-in-youth-with-normal-weight-overweight-and-obesity-at-risk-for-type-2-diabetes-t2d-100460586","NCT05277558","Brain Health in Youth With Normal Weight, Overweight and Obesity at Risk for Type 2 Diabetes (T2D)","Brain Health Across the Metabolic Continuum in Youth at Risk for Type 2 Diabetes (T2D)","Metabrain","Inclusion Criteria:\n\n* 12-17 yrs. old at visit 1, 12-19 yrs. old at visit 2, Tanner II or above (determined through an exam by a pediatric endocrinologist or certified nurse practitioner trained in pediatric endocrinology), otherwise healthy except for obesity, \\\u003C450 lbs. (due to MRI scanner limits), able and willing to lie flat within the MRI scanner and do cognitive testing, fluent in English.\n\nExclusion Criteria:\n\n* Syndromic obesity, history of bariatric surgery, insulin treatment (metformin allowed if \\\u003C 6 months) for T2D, contraindications for MRI (metal, claustrophobia), braces, pregnant (pregnancy test will be done on post-menarchal girls) or breastfeeding, inability to participate in cognitive testing due to sensory or language issues, intellectual disability, special education, pharmacologic treatment for Attention Deficit Hyperactivity Disorder (ADHD), prematurity (\\\u003C36 weeks gestation), complications at birth, neurologic co-morbidities (e.g., seizures, stroke, head injury with \\>10 min loss of consciousness), significant psychiatric disorders (e.g., schizophrenia, bipolar disorder, current major depression), taking psychoactive medications (e.g., antipsychotics) that would interfere with testing or reporting illegal drug use. Self-reported smoking and alcohol use and length of time with obesity will be assessed by history (although these measures may not be fully reliable).","12 Years","17 Years",{"count":133,"type":23},117,"Investigators propose to study youth across the spectrum of body mass index (BMI) and dysglycemia. This approach will allow investigators to disentangle the relationship of key features of type 2 diabetes (T2D) risk (e.g. obesity) with intermediary physiologic changes (e.g. insulin resistance, inflammation, β-cell dysfunction and dysglycemia) that pose a risk for the brain. Investigators will determine which of these factors are most associated with differences in brain structure and function among groups, over time, and how these effects differ from normal neurodevelopment.",[28,136,137,138,139,140,141,35,142,143,144],"Type 2 Diabetes Mellitus in Obese","Dysglycemia","Microvascular Complications","Brain Structure","Obesity, Childhood","Diabetes in Adolescence","Insulin Resistance","Overweight, Childhood","Cognitive Decline",[146],"Brain, Health, Youth, Type 2 Diabetes Mellitus, overweight, obesity","2025-12-16",{"date":149,"type":61},"2025-12-18",{"date":151,"type":61},"2022-05-24",{"date":153,"type":23},"2027-10-31",{"name":155,"class":68},"Washington University School of Medicine",{"id":157,"slug":158,"hasResults":11,"nctId":159,"briefTitle":160,"officialTitle":160,"acronym":161,"eligibilityCriteria":162,"healthyVolunteers":11,"sex":18,"minAge":77,"maxAge":4,"enrollmentInfo":163,"targetDuration":4,"studyType":24,"phases":4,"briefSummary":165,"conditions":166,"keywords":4,"overallStatus":57,"whyStopped":4,"lastUpdateSubmitDate":167,"lastUpdatePostDateStruct":168,"startDateStruct":170,"completionDateStruct":172,"leadSponsor":174,"locationsCount":177},"100443668","uk-imaging-diabetes-study-seeing-diabetes-clearly-100443668","NCT05057403","UK Imaging Diabetes Study Seeing Diabetes Clearly","UKIDS","Inclusion Criteria:\n\n* Male or female at least 18 years of age and diagnosed with type 2 diabetes, with or without diabetic retinopathy.\n* Participant willing and able to give informed consent for participation in the study.\n\nExclusion Criteria:\n\nIn 12 months prior to consent, evidence of existing cardiovascular event defined as at least one of:\n\n* myocardial infarction\n* ischaemic stroke\n* hospital admission\u002Fdischarge for unstable angina\n* heart surgery\n* unstable angina\n* transient ischemic attack\n* The participant may not enter the study if they have any contraindication to magnetic resonance imaging (standard MR exclusion criteria including pregnancy, extensive tattoos, pacemaker, shrapnel injury, severe claustrophobia).\n* Patients with known autoimmune hepatitis, viral hepatitis, Wilson's disease or known significant structural renal tract abnormality.\n* Patients with known alcohol dependency.\n* Any other cause, including a significant disease or disorder which, in the opinion of the investigator, may either put the participant at risk because of participation in the study, or may influence the participant's ability to participate in the study",{"count":164,"type":23},1000,"Prospective, observational cohort study to cross-sectionally assess the health of multiple organs, using multiparametric abdominal magnetic resonance imaging (MRI) scan, and understand if resulting MRI metrics can predict future clinical events over a period of 5 years, in adult patients with type 2 diabetes lacking history of cardiovascular disease.",[28],"2025-11-27",{"date":169,"type":61},"2025-12-05",{"date":171,"type":61},"2022-05-30",{"date":173,"type":23},"2034-06",{"name":175,"class":176},"Perspectum","INDUSTRY",12,{"id":179,"slug":180,"hasResults":11,"nctId":181,"briefTitle":182,"officialTitle":183,"acronym":4,"eligibilityCriteria":184,"healthyVolunteers":11,"sex":18,"minAge":77,"maxAge":185,"enrollmentInfo":186,"targetDuration":4,"studyType":81,"phases":188,"briefSummary":190,"conditions":191,"keywords":192,"overallStatus":57,"whyStopped":4,"lastUpdateSubmitDate":199,"lastUpdatePostDateStruct":200,"startDateStruct":202,"completionDateStruct":204,"leadSponsor":206,"locationsCount":121},"100544859","small-bowel-diversion-100544859","NCT06374368","Small Bowel Diversion","Jejuno-Ileal and Jejuno-Colic Diversion as a New Bariatric Method in the Treatment of Diabetes and Obesity: Study Protocol for a Prospective Randomised Clinical Trial","Inclusion Criteria:\n\n* age 18-65 years at screening;\n* Body mass index ≥30 or ≤50kg\u002Fm2;\n* If subject has Type 2 Diabetes: fasting plasma glucose greater than 6,1 mmol\u002Fl at time of enrollment if not treated with anti-diabetic medication;\n* If on no diabetes medications, Hemoglobin A1C between and including 6.5 and 9.0 at time of enrollment.\n\nExclusion Criteria:\n\n* Body Mass Index \\>50 or \\\u003C30 kg\u002Fm2;\n* Diagnosis of Type 2 diabetes less than 6 months;\n* History of suspected gastrointestinal disease (for example cirrhosis, inflammatory bowel disease);\n* History of active malignancy (not in remission) with the exception of squamous or basal cell carcinoma of the skin;\n* Ongoing systemic infection;\n* Chronic pancreatitis;\n* Chronic liver disease of any cause;\n* Poorly controlled psychiatric disease (for example ongoing major depression, schizophrenia, borderline personality, suicidality, psychosis);\n* Any history of an eating disorder within the past 5 years;\n* Pre-existing severe comorbid cardio-respiratory disease (for example congestive heart failure, cardiac arrhythmia, coronary artery disease, chronic obstructive lung disease, pulmonary embolism);\n* uncontrolled hypertension (systolic Blood Preassure \\> 150 mm Hg or diastolic Blood Preassure \\> 100 mm Hg).","65 Years",{"count":187,"type":23},80,[189],"NA","In an effort to replicate metabolic surgery's durable results in metabolic disease while minimizing its risks, two innovative methods has been created. Two surgical methods to create a bowel-to-bowel anastomosis, similar to the type used in current metabolic surgeries. It be to create a jejuno-ileal, side-to-side anastomosis and jejunocolic side-to-side anastomosis. The side-to-side jejuno-ileal anastomosis and side-to-side jejunocolic anastomosis provides two routes for ingested food. The new, shorter route has a malabsorptive effect similar to that seen in Roux en-Y gastric bypass (RYGB) and biliopancreatic diversion (BPD) - procedures which leads to weight loss. Additionally, delivery of non-absorbed macronutrients to the distal ileum, or transverse colon can enhance incretin effect and improve Type 2 Diabetes Mellitus parameters. However, the native route is also preserved, which theoretically reduces the risk of malnutrition, diarrhea, and metabolic derangements seen in other metabolic surgeries.The side-to-side jejuno-ileal anastomosis was already tested in the Pilot Study of the GI Windows Self-Forming Magnetic (SFM) Anastomosis Device for Creation of an Incisionless Small Bowel Bypass for Treatment of Obesity and Diabetes in year 2015 (15). The results of this study demonstrated the safety of this approach without serious adverse events. This non-surgical approach resulted in significant weight loss, favorable changes in insulin and incretin responses to a mixed meal and significant improvement in HbA1c in T2DM (16).In summary, metabolic diseases are a growing pandemic with suboptimal clinical solutions. The surgical side-to-side jejuno-ileal anastomosis and side-to-side jejuno-colic anastomosis without gastrectomy potentially represents a new class of therapy that may produce durable clinical results generally associated with surgery while minimizing its attendant risks.",[30,28],[30,193,194,195,196,197,198],"Type 2 Diabetes","Partial Jejunal Diversion","Partial Jejuno-colic Diversion","Bariatric surgery","Metabolic surgery","Side-to-Side Anastomosis","2025-08-13",{"date":201,"type":61},"2025-08-19",{"date":203,"type":61},"2019-05-01",{"date":205,"type":23},"2028-12-31",{"name":207,"class":68},"University of Ostrava",{"id":209,"slug":210,"hasResults":11,"nctId":211,"briefTitle":212,"officialTitle":213,"acronym":214,"eligibilityCriteria":215,"healthyVolunteers":11,"sex":18,"minAge":77,"maxAge":185,"enrollmentInfo":216,"targetDuration":4,"studyType":81,"phases":218,"briefSummary":219,"conditions":220,"keywords":222,"overallStatus":57,"whyStopped":4,"lastUpdateSubmitDate":223,"lastUpdatePostDateStruct":224,"startDateStruct":226,"completionDateStruct":228,"leadSponsor":230,"locationsCount":69},"100440437","efficacy-and-safety-of-one-anastomosis-versus-roux-en-y-gastric-bypass-for-type-2-diabetes-remission-100440437","NCT05015283","Efficacy and Safety of One-anastomosis Versus Roux-en-Y Gastric Bypass for Type 2 Diabetes Remission","Efficacy and Safety of One-anastomosis Versus Roux-en-Y Gastric Bypass for Type 2 Diabetes Remission (ORDER): a Multi-centric, Randomized, Open-label, Superiority Trial","ORDER","Inclusion Criteria:\n\n* 21-65 years old, Male\u002FFemale, East Asian population\n* 50 kg\u002Fm2≥BMI≥27.5kg\u002Fm2\n* Type 2 diabetes duration ≥6 months\n* HbA1c≥7.0%\n* Currently receiving one or more oral\u002Finjectable hypoglycemic drugs (insulin \u002Fglucagon-like peptide-1 receptor agonist)\n* Recommendation for OAGB\u002FRYGB evaluated by a multidisciplinary team\n\nExclusion Criteria:\n\n* Underwent gastrointestinal surgery (gastric\u002Fduodenal surgery or bariatric surgery)\n* Fasting C-peptide level lower than 1\u002F2 normal minimum\n* Active gastrointestinal ulcer is present\n* Helicobacter pylori infection is present\n* A history of serious cardiovascular and cerebrovascular diseases (myocardial infarction, stroke, etc.)\n* A history of cirrhosis (Child-Pugh≥A)\n* A history of chronic kidney disease (eGFR )\\\u003C 60 ml\u002Fmin \u002F 1.73 m2)\n* Inflammatory bowel disease is present (ulcerative colitis, Crohn's disease)\n* Chronic anemia is present, Hgb for male \\\u003C100g\u002FL, for female \\\u003C90g\u002FL\n* A desire to conception during the study period\n* Uncontrolled mental and psychological disorders are present\n* Expected survival\\\u003C5 years of end-stage disease or previous\u002Fcurrent malignant tumor\n* Participated in clinical studies\u002Ftrials that have the conflict of interest with the study\n* Unable to understand, refuse to participate and sign the informed consent\n* Gallstones require cholecystectomy\n* Reflux esophagitis above grade A",{"count":217,"type":23},248,[189],"Diabetes mellitus (T2DM) is the most common complication of obesity patients. According to previous literature reports, weight loss and metabolic surgery are powerful means to treat obesity complicated with T2DM. Roux-en-Y gastric bypass (RYGB) is the standard operation recommended by the international society. One-anastomosis gastric bypass (OAGB) was recommended by IFSO（the International Federation for the Surgery of OBESITY AND METABOLIC DISORDERS ） in 2018.\n\nIn this study, two kinds of metabolic surgery will be compared. At present, focusing on the above two operations, only two effective randomized controlled clinical studies have been carried out, among which one single-center clinical study has been followed up for 2 years, and the primary end point is weight loss; Another multicenter study, with a 2-year follow-up, showed that the primary end point was weight loss, and the secondary index was the effectiveness of two surgical methods in the treatment of T2DM.There is still a lack of evidence-based evidence for the effectiveness and safety of the two surgical methods in the treatment of T2DM. This study will make high-level evidence about the advantages and disadvantages of OAGB and RYGB in the treatment of T2DM.\n\nIn this study, a number of centers with rich experience and clinical research experience in weight loss and metabolic surgery in Asia will be combined to complete the enrollment of 248 patients. Those who meet the standards will be randomly divided into two kinds of operations, and they will be followed up for 5 years on schedule. The rate of lost follow-up is controlled within 20%, and the data integrity is controlled within 95%. Taking the blood glucose remission rate of type 2 diabetes as the main observation index, the prospective verification shows that OAGB is clinically effective in treating obesity with type 2 diabetes compared with RYGB.",[28,221],"Complication of Bariatric Procedure",[196],"2022-08-01",{"date":225,"type":61},"2022-08-03",{"date":227,"type":61},"2022-02-01",{"date":229,"type":23},"2026-12-31",{"name":231,"class":68},"Beijing Friendship Hospital",{"id":233,"slug":234,"hasResults":11,"nctId":235,"briefTitle":236,"officialTitle":236,"acronym":237,"eligibilityCriteria":238,"healthyVolunteers":17,"sex":18,"minAge":77,"maxAge":20,"enrollmentInfo":239,"targetDuration":4,"studyType":81,"phases":241,"briefSummary":242,"conditions":243,"keywords":244,"overallStatus":249,"whyStopped":4,"lastUpdateSubmitDate":250,"lastUpdatePostDateStruct":251,"startDateStruct":253,"completionDateStruct":255,"leadSponsor":257,"locationsCount":4},"100432180","personalized-follow-up-program-in-the-type-2-diabetes-prevention-100432180","NCT04907760","Personalized Follow-up Program in the Type 2 Diabetes Prevention","PROXIPART","Inclusion Criteria:\n\n* Person with a FINDRISC score ≥ 10 points\n* Person who has given his\u002Fher express written and informed consent\n\nExclusion Criteria:\n\n\\- Person already diagnosed with a type 2 diabetes",{"count":240,"type":23},230,[189],"In France, the global prevalence of diabetes was estimated to 5% of the population in 2016, the type two diabetes (DT2) corresponding to 90% of cases. This number is widely underestimated because most people are untreated and undiagnosed. Due to the silent character of this disease, it is estimated that 20 à 30 % of diabetic adults have not yet been diagnosed. The conclusions, presented during the annual meeting of EASD in 2019, suggest that the precursor signs of this disease could be present until 20 years before the diagnosis.\n\nDiabetes is a metabolic disease and people are diagnosed, in general, around 40-50 years old. The main risk factor of type II diabetes is lifestyle (rich diet, sedentary) but there is also other factors like hyperlipidemia, high blood pressure, high fasting blood sugar, stress, smoking, heredity, family history of diabetes, or gestational diabetes. This induces an increase of obesity, itself a major risk factor for type II diabetes occurrence.\n\nFrom an economical aspect, chronic pathologies (including diabetes) represent 60% of health insurance expenses, even though it concerns 35% of insured persons, i.e. 20 million of patients. The average of annual reimbursement for a type 2 diabetic patient is 4890 euros. In this context, this study is the first step of thinking about a different, coordinated care approach, based on a preventive rather than curative approach.",[28],[245,246,247,248],"Diabetes","Metabolic Diseases","Endocrine System Diseases","Prevention","NOT_YET_RECRUITING","2021-09-14",{"date":252,"type":61},"2021-09-16",{"date":254,"type":23},"2021-10-10",{"date":256,"type":23},"2026-10-10",{"name":258,"class":68},"GCS Ramsay Santé pour l'Enseignement et la Recherche",{"id":260,"slug":261,"hasResults":11,"nctId":262,"briefTitle":263,"officialTitle":264,"acronym":265,"eligibilityCriteria":266,"healthyVolunteers":17,"sex":267,"minAge":77,"maxAge":4,"enrollmentInfo":268,"targetDuration":4,"studyType":81,"phases":270,"briefSummary":271,"conditions":272,"keywords":4,"overallStatus":57,"whyStopped":4,"lastUpdateSubmitDate":275,"lastUpdatePostDateStruct":276,"startDateStruct":278,"completionDateStruct":280,"leadSponsor":282,"locationsCount":69},"100378376","iglucose-remote-patient-monitoring-device-as-an-adjunct-to-routine-glucose-meter-devices-for-glycemic-management-and-control-in-gestational-diabetes-100378376","NCT04206748","iGlucose® Remote Patient Monitoring Device as an Adjunct to Routine Glucose Meter Devices for Glycemic Management and Control in Gestational Diabetes","iGlucose® Remote Patient Monitoring Device as an Adjunct to Routine Glucose Meter Devices for Glycemic Management and Control in Gestational Diabetes: a Pilot Randomized, Controlled Trial","iGlucose","Inclusion Criteria\n\n* All patients \\>\u002F= women 18 years of age with gestational diabetes or type 2 diabetes during pregnancy and identified by the research team and consented before 30.6 weeks.\n* Non-anomalous singletons\n* Ability to provide informed consent\n\nExclusion Criteria\n\n* Patients with Type 1 diabetes\n* Patients with fetal major congenital abnormalities\n* Patients identified\u002Freferred after 30.6 weeks","FEMALE",{"count":269,"type":23},200,[189],"The purpose of this study is to investigate whether automation of glucose monitoring data to facilitate the total number of recommended and completed SMBG checks improve clinical outcomes for women living with gestational and type 2 diabetes during pregnancy? This is a RCT",[273,28,274],"Gestational Diabetes","Pregnancy in Diabetic","2021-09-01",{"date":277,"type":61},"2021-09-02",{"date":279,"type":61},"2019-11-12",{"date":281,"type":23},"2022-11-01",{"name":283,"class":68},"The University of Texas Health Science Center, Houston",{"id":285,"slug":286,"hasResults":11,"nctId":287,"briefTitle":288,"officialTitle":288,"acronym":289,"eligibilityCriteria":290,"healthyVolunteers":17,"sex":18,"minAge":77,"maxAge":291,"enrollmentInfo":292,"targetDuration":4,"studyType":81,"phases":294,"briefSummary":295,"conditions":296,"keywords":300,"overallStatus":57,"whyStopped":4,"lastUpdateSubmitDate":311,"lastUpdatePostDateStruct":312,"startDateStruct":314,"completionDateStruct":316,"leadSponsor":318,"locationsCount":69},"100297781","stop-diabetes---knowledge-based-solutions-100297781","NCT03156478","STOP DIABETES - Knowledge-based Solutions","StopDia","Inclusion Criteria:\n\n* age of 18-70 years\n* 12 points or more in the Finnish diabetes risk score or previous gestational diabetes or repeated impaired fasting glucose (IFG) (fasting plasma glucose level 6,1 - 6,9 mmol\u002Fl) or impaired glucose tolerance (2-hour glucose level 7,8 - 11,0 mmol\u002Fl in oral glucose tolerance test)\n* living in the hospital district of Northern Savo, Päijät-Häme or South Karelia\n* possibility to use computer, smartphone or tablet with internet connection\n* having own self-phone number\n* adequate Finnish language skill\n\nExclusion Criteria:\n\n* type 1 or 2 diabetes\n* pregnancy or breastfeeding\n* current cancer or less than 6 months from the end of cancer treatment","70 Years",{"count":293,"type":23},10000,[189],"The aim of the Stop Diabetes - Knowledge based solutions (StopDia) consortium project (University of Eastern Finland, National Institute for Health and Welfare, and Technical Research Centre of Finland) is to develop and test approaches to identify individuals at increased risk of type 2 diabetes and to empower them in adopting and maintaining a healthy lifestyle by combining individual and environment level strategies into a dual-process approach targeting deliberative and automatic processes of behavior. We also aim to identify barriers and facilitators of adopting a healthy lifestyle in the society, create a model for the prevention of type 2 diabetes by joint actions of health care, third sector, and other societal actors, and develop methods to monitor the cost-effectiveness of these actions. We will carry out a 1-year randomized controlled trial on the effects of among 10 000 individuals aged 18-70 years at increased risk of type 2 diabetes living in Finland. The participants will be randomized into the control group, the digital lifestyle intervention group, or the combined digital and face-to-face lifestyle intervention group. The aim of the interventions is to enhance diet quality, increase physical activity, decrease body weight, and improve glucose tolerance in individuals at increased risk of type 2 diabetes.",[28,297,40,298,299],"Life Style","Physical Activity","Empowerment",[248,301,302,303,304,305,306,307,308,309,310],"Digital solutions","Type 2 diabetes","Life style modification","Physical activity","Healthy diet","Health economics","Environmental choice architecture","Socio-economic facilitators","Socio-economic barriers","Wellbeing","2017-05-15",{"date":313,"type":61},"2017-05-17",{"date":315,"type":61},"2017-04-10",{"date":317,"type":23},"2037-12",{"name":319,"class":68},"University of Eastern Finland"]